Luspatercept is a medication that works by increasing the production of red blood cells in people with anemia caused by beta thalassemia or myelodysplastic syndromes. It is a recombinant fusion protein consisting of truncated activin receptor type IIA and the Fc portion of human IgG1. The drug is administered as an intravenous infusion every three weeks. Luspatercept has been shown to be effective in reducing the need for red blood cell transfusions in patients with these diseases.
Luspatercept, sold under the brand name Reblozyl, is a medication used for the treatment of anemia in two blood disorders: beta thalassemia and myelodysplastic syndromes (MDS) [1]. It is a first-in-class medication, meaning it has a unique mechanism of action compared to other drugs used to treat these conditions [1].
Here's a summary of how Luspatercept works:
- It is a recombinant fusion protein, which means it's an engineered protein made by combining parts of two different proteins [2].
- One part of Luspatercept binds to transforming growth factor-beta (TGF-beta) ligands, which are signaling molecules in the body [2].
- By binding to these ligands, Luspatercept reduces SMAD2 and SMAD3 signaling, which are pathways involved in cell growth and differentiation [2].
- In the case of red blood cells, this reduction in signaling helps them mature properly, thereby reducing anemia [2].
Luspatercept is typically given as a subcutaneous injection (under the skin) once every three weeks [3].
Important things to know about Luspatercept:
- It is not a substitute for red blood cell transfusions in people who need immediate treatment for anemia [3].
- The most common side effects of Luspatercept include fatigue, headache, bone pain, and nausea [3].
- Luspatercept can interact with other medications, so it is important to tell your doctor about all the medications you are taking before starting treatment [3].